PRINCETON, N.J., Oct. 6 /PRNewswire/ -- Laureate Pharma, Inc., a full-service contract development and manufacturing organization today announced that it has secured $20 million in debt and equity financing to enhance and grow its business.
Building on nearly 30 years of experience in the development and supply of protein drug products produced from mammalian cell culture, Laureate Pharma will be able to better serve its clients by accelerating their timelines from development through production.
"Today marks a significant milestone in our efforts to relaunch Laureate Pharma," said Michael A. Griffith, Chief Executive Officer. "Our strategically planned improvements coupled with our solid financial footing will position us for exceptional growth."
Mr. Griffith continued, "As we transform Laureate, care will be taken to maintain continuity of client services. Quality Assurance will oversee investment activities to ensure our offerings comply with the strict demands of global regulatory agencies."
The new funds will be used to drive five investment initiatives over a three-year period and will provide a more robust portfolio of services to better serve customers' needs and include:
Laureate Pharma has added 10 new jobs since bringing on a new CEO and a new Vice President of Business Development and plans to fill 50 more positions when working at capacity.
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical contract development and manufacturing organization. Laureate's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.
About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.
For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Pharma, at (609) 919-3367, or email@example.com or visit www.laureatepharma.com or Jennifer Vollaro at Integrated Marketing Services at (609) 683.9055 ext. 247, or firstname.lastname@example.org.
|SOURCE Laureate Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved